United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$233.85 USD
-2.10 (-0.89%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $233.96 +0.11 (0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Brokerage Reports
0 items in cart
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 561 - 580 ( 585 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
FREEDOM-C2 Trial Enrolled with Data Anticipated in September
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4 Financials Missed But Not Material in our View
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4 Preview: We Believe Q4 Consensus Is a Bit High; However, Since UTHR Is Trading In-Line, We Anticipate a Small Miss Won''t Be Material. Raising FV to $77 from 72
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
2011 Major Value Drivers in Emerging Pharmaceuticals.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q3 Financials Beat Due To Strong Product Sales. Raising Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q3 Preview: We Believe Q3 Consensus Is A Bit High. However, Since UTHR Is Trading In-Line, We Anticipate A Small Miss Wont Be Material.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q2 Financials Beat: Lower Operating Expenses And Strong Adcirca Sales Led To GAAP EPS Beat
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q2 Preview: We Believe Q2 Consensus Is Somewhat High. However, Since UTHR Is Trading In-Line With Comparables, We Dont Expect A Small Miss To Be Material.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso Accelerates Top-Line Growth.
Provider: AURIGA USA
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1 Financials Beat: Tyvaso Strength Was Understandable But Is Remodulins Q1 Strength Sustainable?
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1 Preview: We Think Q1 Will Be Either In-Line Or Squeak By Consensus--Tyvaso Is The Wild Card.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso Uptake Looks Strong - Reiterate Buy.
Provider: AURIGA USA